Table 4.
Self-Reported Motor Dysfunction 1 Month After Surgery (Number of Respondents Both at Baseline and 1 Month = 93/155)
| Patient Characteristics | Did Not Complete Questionnaires at Inclusion and/or 1 Month N: 62/155 |
No Difference N: 35/93 (38%) |
Improved Motor Dysfunction N: 28/93 (30%) |
Worse Motor Dysfunction N: 30/93 (32%) |
|---|---|---|---|---|
| ECOG status | ||||
| 0–1 | 37 (60%) | 28 (80%) | 17 (61%) | 23 (77%) |
| 2 | 17 (27%) | 6 (17%) | 6 (21%) | 5 (17%) |
| 3–4 | 7 (11%) | 1 (3%) | 4 (14%) | 2 (7%) |
| Missing | 1 | 0 | 1 | 0 |
| Primary cancer | ||||
| Lung | 19 (31%) | 13 (37%) | 11 (39%) | 9 (30%) |
| Melanoma | 11 (18%) | 7 (20%) | 5 (18%) | 7 (23%) |
| Breast | 12 (19%) | 5 (14%) | 4 (14%) | 4 (13%) |
| Colorectal | 8 (13%) | 6 (17%) | 5 (18%) | 4 (13%) |
| Othera | 12 (19%) | 4 (11%) | 3 (11%) | 6 (20%) |
| Number of brain metastases | ||||
| 1 | 48 (77%) | 24 (68%) | 18 (64%) | 18 (60%) |
| 2–4 | 12 (19%) | 9 (26%) | 8 (29%) | 8 (27%) |
| >4 | 2 (3%) | 2 (6%) | 2 (7%) | 4 (13%) |
| Age ≥70 | 23 (37%) | 16 (46%) | 9 (32%) | 13 (43%) |
| Extracranial metastases present | 35 (56%) | 21 (60%) | 15 (54%) | 17 (57%) |
| Brain metastasis location | ||||
| Motor area | 19 (54%) | 12 (43%) | 13 (43%) | |
| Non-motor area | 16 (46%) | 15 (54%) | 17 (57%) | |
| Missing | 0 | 1 | 0 | |
| Extent of resection | ||||
| Gross total resection | 31 (50%) | 16 (46%) | 12 (43%) | 10 (33%) |
| Gross total resection with other brain metastases remaining | 4 (6%) | 5 (14%) | 4 (14%) | 10 (33) |
| Subtotal resection | 24 (39%) | 14 (40%) | 11 (39%) | 10 (33) |
| Unknown | 3 (5%) | 0 (0%) | 1 (4%) | 0 (0%) |
| Motor dysfunction score at inclusion (mean) | 28.8 (SD: 22.3) | 8.9 (SD: 13.4) | 37.3 (SD: 26.6) | 15.9 (SD: 17.4) |
| Motor dysfunction score at 1 month (mean) | 8.9 (SD: 13.4) | 15.5 (SD: 20.6) | 33.7 (SD: 22.7) | |
| Difference in motor dysfunction score | 0.0 | −21.8 (SD: 14.7) | 17.8 (SD: 11.5) | |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aRenal cancer, esophageal cancer, testicular cancer, ovarian cancer, bladder cancer, uterine cancer, and origo incerta.